All compound families validated in both prostate and pancreatic cancer (TCGA-PAAD confirmed).
| Target | Compounds | Indications | Readiness |
|---|---|---|---|
| CRYZ | 100 | Prostate + Pancreatic | 2 wet-lab-ready |
| ATP1A4 | 3 | Prostate + Pancreatic | 54 PDAC cases — HIGH |
| METAP1D | 12 | Prostate + Pancreatic | Active screening |
| BRD4 | 223 | Pan-cancer | Parked (crowded space) |
| Quantum VQE Run | $5,000/run | IonQ binding energy, error mitigation, 200 restarts, human-approved | |
| Quantum Package (5) | $25,000 | 5 VQE runs, bulk discount |
| Asset | Stage | Deal Type | Value Proposition |
|---|---|---|---|
| METAP1D program (12 compounds) | Advanced validated | Exclusive license | First-in-class, no competition, quantum-validated |
| CRYZ program (100 compounds) | 2 wet-lab-ready | Exclusive license | First-in-class, novel mechanism, ready for assay |
| BRD4/BET portfolio (223 compounds) | Parked | Non-exclusive / bulk | Strong Vina scores, novel scaffolds, GenChem-generated |
| ATP1A4 program (3 compounds) | Grade A | Co-development | Ion pump target, cardiac glycoside derivatives |
| Kit | Use Case | Partner Type |
|---|---|---|
| PRR36 CDx | BET drug discovery program companion diagnostic | Pharma (BET program owners) |
| STX19 CDx | EGFR trafficking — predict resistance | Pharma (EGFR programs) |
| ARSF Prognostic | Sulfatase-linked survival stratification | Diagnostics companies |
| Multi-gene Panel | PRR36 + STX19 + TM7SF2 | Clinical labs |
| Immunotherapy Exclusion | Keytruda non-responder redirect | Pharma (IO programs) |
| Subtype Classifier | Group 1 vs Group 2 treatment selection | Precision oncology platforms |
| Service | What You Get | Pricing Model |
|---|---|---|
| Discovery Vault Access | 10,606 candidates with evidence certificates | Annual subscription |
| Custom Discovery | Run governed pipeline on your cancer type/target | Per-project fee |
| Signal Evaluation | Apply our diagnostic kits to your patient data | Per-sample fee |
• First-in-class targets — METAP1D and CRYZ have zero existing drugs
• Governed pipeline — every decision has cryptographic proof
• Honest scoring — we don't inflate confidence (scores capped at 0.60 pre-wet-lab)
• Full evidence chain — hash-chained certificates from generation to validation
• AI-augmented — Cortex brain improves nightly, quantum validation available
• Low burn — $3/month infrastructure, capital-efficient
Licensing inquiries: partnerships@mindnetq.com
Platform services: platform@mindnetq.com
MindNetQ Inc. — Governed Intelligence for Precision Medicine
| Service | Price | What You Get |
|---|---|---|
| Cortex Starter | $2,500/mo | 10 queries, reasoning, nightly learning, 7-day trial |
| Cortex Pro | $15,000/mo | 100 queries, private memory, monitoring, competitor intel, API |
| Cortex Enterprise | $50,000+/mo | Unlimited, dedicated shard, custom modules, SLA, HIPAA |
| MindNetQ Cortex Research Job | $2,000-$5,000/job | Full multi-omics pipeline, real-time, governed Research Object |
| MindNetQ Cortex Institutional | $150-300K/yr | Unlimited users, private datasets, federated |
| MindNetQ Cortex Enterprise | $500K-1M/yr | Sovereign deployment, full governance instance |
Cortex = smart agentic AI (reasoning, learning, monitoring). MindNetQ Cortex = governed multi-omics execution. They enrich each other.